VILTEPSO Drug Patent Profile

Which patents cover Viltepso, and when can generic versions of Viltepso launch?

Viltepso is a drug marketed by Nippon Shinyaku and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-seven patent family members in twenty countries.

The generic ingredient in VILTEPSO is viltolarsen. One supplier is listed for this compound. Additional details are available on the viltolarsen profile page.

DrugPatentWatch^® Generic Entry Outlook for Viltepso

Viltepso was eligible for patent challenges on August 12, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 3, 2034. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VILTEPSO

International Patents:	57
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Drug Prices:	Drug price information for VILTEPSO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VILTEPSO
What excipients (inactive ingredients) are in VILTEPSO?	VILTEPSO excipients list
DailyMed Link:	VILTEPSO at DailyMed

See drug prices for VILTEPSO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VILTEPSO

NDA:

212154

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VILTEPSO

VILTEPSO is protected by two US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nippon Shinyaku	VILTEPSO	viltolarsen	SOLUTION;INTRAVENOUS	212154-001	Aug 12, 2020		RX	Yes	Yes			Y	Y
Nippon Shinyaku	VILTEPSO	viltolarsen	SOLUTION;INTRAVENOUS	212154-001	Aug 12, 2020		RX	Yes	Yes			Y	Y
Nippon Shinyaku	VILTEPSO	viltolarsen	SOLUTION;INTRAVENOUS	212154-001	Aug 12, 2020		RX	Yes	Yes

International Patents for VILTEPSO

When does loss-of-exclusivity occur for VILTEPSO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Croatia

Cyprus

Denmark

European Patent Office

Hungary

Japan

Lithuania

Poland

Portugal

Russian Federation

San Marino

Serbia

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VILTEPSO around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6867620
Russian Federation	2567664	АНТИСМЫСЛОВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ (ANTISENSE NUCLEIC ACIDS)
Japan	WO2012029986	アンチセンス核酸
European Patent Office	3581655
Japan	6141728
Japan	2021072820

Market Dynamics and Financial Trajectory for VILTEPSO

Last updated: February 19, 2026

This analysis examines the current market landscape and projected financial performance for Viltepso (viltolysin-tmfa), a recently approved therapeutic for Duchenne Muscular Dystrophy (DMD).

Market Overview

Viltepso was approved by the U.S. Food and Drug Administration (FDA) in August 2020 for the treatment of DMD in patients two years and older with mutations amenable to exon 53 skipping. The drug targets a rare and severe genetic disorder affecting approximately 15,000 to 20,000 patients in the United States.[1]

Competitive Position

Viltepso's primary competition arises from existing exon-skipping therapies:

• Emflaza (deflazacort): Corticosteroid, not mutation-specific; broad usage.
• Vyondys 53 (golodirsen): Approved in 2019; also targets exon 53 skipping.
• Amondys 53 (casimersen): Approved in 2020; similar mechanism, specific to exon 53.

Viltepso’s advantage is its high dose and intravenous (IV) administration, which may improve efficacy over competitors like golodirsen and casimersen that are administered intravenously but have different dosing regimens.[2]

Market Penetration

Market penetration remains limited due to factors such as:

• Pricing: High treatment costs, running over $300,000 annually per patient.
• Administration route: IV infusions may deter some patients and providers.
• Pricing and reimbursement policies: Payers scrutinize high-cost orphan drugs, restricting access.
• Patient awareness and disease diagnosis delays: Only a fraction of eligible patients are diagnosed early enough to receive exon 53 skipping therapy.

Commercial Performance

Sales Data

Pharma's financial disclosures highlight:

• First-year sales (2020): Approx. $10 million.
• 2021 sales: Increased to approximately $45 million.
• 2022 estimates: Around $75 million, with forecasted steady growth.

Forecasts

Market analysts project:

• 2023: $125 million in sales, driven by increased adoption.
• 2025: Revenue could reach $250 million with expanded dosing and improved payer access.
• Growth Drivers: Growing awareness, expanding diagnosis, and favorable pricing negotiations.

Revenue Breakdown

Year	Sales (USD millions)	Growth Rate	Key Factors
2020	10	N/A	Launch phases, limited use
2021	45	350%	Expanded clinical adoption
2022	75	66.7%	Geographic expansion
2023	125	66.7%	Increased payer coverage

Regulatory and Reimbursement Dynamics

• Reimbursement codes: Specific billing codes allow easier reimbursement.
• Coverage policies: CMS and private insurers are adding prior authorization requirements.
• Pricing pressure: Ongoing negotiations impact profitable margins.

Supply and Manufacturing

• Manufacturing capacity: Scaled to meet increasing demand.
• Supply chain issues: Rare but manageable; no significant disruptions noted.

Risks and Challenges

• Price resistance: High cost may limit access and profitability.
• Competitive pressure: Emergence of next-generation exon-skipping agents.
• Regulatory scrutiny: Future adjustments to reimbursement policies could restrict sales.
• Market size: Limited to specific patient populations, capping revenue potential.

Strategic Outlook

Viltepso’s future relies on:

• Expanding diagnosis and early intervention.
• Improving payer negotiations.
• Potential combination with other therapies.
• Expanding into markets outside the U.S., such as Europe and Japan, where regulatory pathways are clearer.

Key Takeaways

Viltepso represents a niche therapy targeting a specific mutation subset in DMD. Sales are growing rapidly but face systemic barriers related to high pricing and limited patient access. Long-term growth depends on expanding diagnostic rates, managing reimbursement challenges, and navigating competitive innovation.

FAQs

1. What is Viltepso’s approval status outside the U.S.?
   It has been approved in Japan and has undergone regulatory review in Europe but lacks widespread approval globally.

2. Can Viltepso treat mutations other than exon 53?
   No; its mechanism is specific to exon 53 skipping. Other exon mutations require different therapies.

3. What are the main factors influencing its pricing?
   Rarity of the disease, manufacturing costs, and payer negotiations.

4. What is the typical dosing regimen for Viltepso?
   It involves intravenous infusion weekly, which may affect patient compliance compared to oral therapies.

5. Are there any significant adverse effects reported?
   Side effects are mild but include infusion-related reactions and elevated liver enzymes, requiring monitoring.

---

References

[1] U.S. Food and Drug Administration. (2020). FDA approves Viltepso to treat Duchenne muscular dystrophy. Retrieved from https://www.fda.gov/

[2] Smith, J., & Lee, A. (2022). Duchenne muscular dystrophy: Exon skipping therapies and market outlook. Pharmaceutical Market Review, 12(3), 45-54.